Demeprazol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Demeprazol

What is Demeprazol?

Demeprazol is a pharmaceutical formulation containing omeprazole, a therapeutic agent belonging to the class of medications known as proton pump inhibitors (PPIs). It is primarily utilized to manage conditions associated with excessive gastric acid production.

Mechanism of Action

The active ingredient works by targeting the parietal cells in the stomach lining. It inhibits the enzyme system known as the hydrogen-potassium ATPase pump, which is the final step in the secretion of hydrochloric acid. By blocking this process, the medication significantly reduces the acidity of the stomach environment.

Primary Uses

Demeprazol is typically indicated for the following conditions:

  • Gastroesophageal Reflux Disease (GERD): To manage symptoms such as heartburn and to allow the esophagus to heal from acid-related damage.
  • Gastric and Duodenal Ulcers: To assist in the healing of existing ulcers and to prevent their recurrence.
  • Zollinger-Ellison Syndrome: To manage rare conditions where the stomach produces extreme amounts of acid.
  • Erosive Esophagitis: To treat inflammation and tissue damage in the food pipe caused by chronic acid exposure.

Therapeutic Role

By maintaining a higher pH level within the stomach, the medication provides a stable environment that facilitates the natural healing of the gastrointestinal mucosa. It is designed for systemic action, providing a prolonged reduction in acid secretion compared to simple antacids that only neutralize existing acid.

What side effects are possible with Demeprazol?

Possible Side Effects and Safety Information

The official safety profile for Demeprazol (Omeprazole) structures adverse reactions based on their frequency in clinical trials and the physiological system affected, adhering to classifications set by regulatory bodies like the FDA and EMA.

Frequency and System Classification

Adverse reactions are classified into frequency tiers, with the most frequently observed effects categorized as Common (reported in ge 1% of patients). These typically involve the Gastrointestinal and Nervous Systems and include headache, abdominal pain, diarrhea, nausea, and flatulence. Reactions classified as Uncommon (ge 0.1% to < 1%) include insomnia, dizziness, and elevated liver enzymes. Rare and very rare classifications address less frequently observed events.


Documented Serious Safety Concerns

The regulatory label highlights specific, often serious, adverse reactions that have been documented. These include severe hypersensitivity reactions such as angioedema and anaphylaxis, and severe cutaneous reactions like Stevens-Johnson syndrome (SJS). Furthermore, a specific safety profile is associated with long-term use (typically one year or longer), which includes an increased risk of bone fracture (hip, wrist, or spine) and Hypomagnesemia (low serum magnesium levels). Prolonged use may also be associated with Vitamin B12 deficiency.


Population-Specific Notes

Caution is noted for patients with hepatic impairment, as the medicine's metabolism may be affected; severe hepatic impairment is a defined safety restriction in some regulatory contexts. Older adults (ge 65 years) may be more susceptible to long-term risks such as bone fracture.

Overdose and Emergency Response

Overdose and When to Seek Help

In the event of a suspected Demeprazol (Omeprazole) overdose, regulatory authorities strictly mandate seeking immediate medical attention or contacting a Poison Control Center right away. This requirement for urgent medical response is based on the need for clinical oversight of documented manifestations.

The official regulatory profile describes a set of clinical signs primarily affecting the central nervous system, cardiovascular system, and the gastrointestinal tract. Specific manifestations reported in regulatory records following substantial exposure levels include confusion, drowsiness, blurred vision, headache, and nausea. Patients may also exhibit autonomic and cardiovascular changes such as flushing, diaphoresis (sweating), dry mouth, and tachycardia (elevated heart rate).

The official management strategy is directly influenced by the finding that no specific antidote is known for omeprazole overdosage. Consequently, the intervention prescribed in regulatory documents is confined to providing symptomatic and supportive treatment to manage the clinical manifestations. Regulatory documentation indicates that symptoms observed in reported overdose cases were generally transient and short-lived, with no serious clinical outcome established in the limited reports. Additionally, it is noted that the active substance is not readily dialyzable due to its extensive protein binding.

Therapeutic Uses of Demeprazol

Main Uses and Benefits of Demeprazol

Demeprazol belongs to a class of medications known as proton pump inhibitors (PPIs). It is primarily used to manage conditions where the reduction of gastric acid secretion is necessary for healing and symptom relief.

Treatment of Acid-Related Conditions

Demeprazol is effective in treating various disorders of the upper gastrointestinal tract. By inhibiting the enzyme system in the stomach wall that produces acid, it creates an environment conducive to tissue repair. Common conditions treated include:

  • Gastroesophageal Reflux Disease (GERD): This medication helps alleviate symptoms such as heartburn and acid regurgitation caused by the backflow of stomach acid into the esophagus.
  • Gastric and Duodenal Ulcers: Demeprazol is used to treat active ulcers in the stomach or the upper part of the small intestine. It helps the ulcerated tissue heal by protecting it from corrosive acid.
  • Erosive Esophagitis: For patients with inflammation or sores in the lining of the esophagus due to chronic acid exposure, this medication assists in healing the damage and preventing recurrence.

Management of Hypersecretory States

In some instances, the body produces excessive amounts of stomach acid due to underlying medical conditions. Demeprazol is utilized to manage these long-term hypersecretory states, such as Zollinger-Ellison syndrome, where it helps maintain acid levels within a manageable range.

Therapeutic Benefits

The primary benefit of Demeprazol is the consistent and prolonged suppression of gastric acid. This reduction in acidity provides several clinical advantages:

  • Symptom Relief: It provides significant relief from the discomfort and pain associated with acid-related disorders.
  • Tissue Healing: By lowering the acidity of gastric juices, it allows the mucosal lining of the esophagus and stomach to recover from erosions and ulcerations.
  • Prevention of Complications: Effective acid management can help prevent further damage to the gastrointestinal tract, such as strictures or Barrett's esophagus, which can result from chronic untreated reflux.

Regulatory References

  1. full prescribing information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Demeprazol (Omeprazole)

Regulatory documents define strict rules for using Demeprazol, the active ingredient of which is Omeprazole.

Eligibility Scope

Classification Status According to Regulatory Documents
Absolute Contraindication Contraindicated in patients with known hypersensitivity to Omeprazole, substituted benzimidazoles, or any component of the formulation. Must not be used concurrently with Rilpivirine-containing products.
Age-Group Eligibility Established for adults. Established for pediatric patients 1 year and older for GERD, and 1 month and older for erosive esophagitis. Safety and effectiveness are not established in infants under 1 month.
Conditional Restrictions Patients with hepatic impairment are eligible for use, but a reduced dose must be considered. Concomitant use with Clopidogrel must be avoided.
Physiological Status Use during pregnancy is restricted, considered only if the benefit outweighs the risk. Use is not recommended during lactation.

Official Eligibility Statement: Use is confined to populations for whom regulatory authorities have formally classified the treatment as permitted, restricted, or contraindicated.

What should I know about interactions with other medicines?

Demeprazol Interactions with other medicines and products

Demeprazol (Omeprazole) may interact with certain medicines and products through two primary documented mechanisms: altering gastric acidity and affecting the metabolism of other drugs.

Official Interaction Restrictions

Classification Interacting Substance Restriction
Contraindicated Nelfinavir, Rilpivirine Co-administration is formally prohibited.
Timing Rule Atazanavir Omeprazole dose must be limited to 20 mg and administered approximately 12 hours apart.
Avoid Use St John's Wort, Rifampin, Clopidogrel Use should be avoided due to significant interaction risk.

Pharmacokinetic and Pharmacodynamic Effects

Demeprazol is known to inhibit the CYP2C19 enzyme, which can increase the plasma concentration of co-administered drugs such as Warfarin, Phenytoin, and Diazepam, requiring careful monitoring. It also increases the systemic exposure of Cilostazol and Tacrolimus.

As a potent gastric acid inhibitor, Demeprazol elevates intragastric pH, which reduces the absorption and efficacy of drugs that require an acidic environment. This applies to antifungals like Ketoconazole and Itraconazole, and the antiretroviral Atazanavir. Long-term use may also reduce the absorption of Vitamin B12. Population-specific caution is advised for patients with Hepatic Impairment, and closer monitoring may be required.

Mechanism of Action

Demeprazol functions as a selective inhibitor of beta-secretase 1 (BACE1), an aspartyl protease centrally involved in specific cellular processes. The molecule achieves its effect by binding directly to the active catalytic site of the BACE1 enzyme. This interaction is characterized by a reversible, non-competitive binding mode, which stabilizes an inactive conformation of BACE1 and sterically blocks access to its endogenous substrate.

This inhibition of BACE1 activity causes a subsequent decrease in the enzyme's proteolytic cleavage of the amyloid precursor protein (APP). APP processing is a key step in a complex intracellular signaling cascade; by limiting the initial cleavage, Demeprazol consequently reduces the generation and production rate of the beta-amyloid peptide (Abeta).

The overall physiological consequence of this reduced Abeta generation is a lowered concentration of the peptide fragments within the neuronal and extracellular space. This molecular outcome directly modulates the aggregation and subsequent deposition of Abeta peptides into insoluble structures within the central nervous system.

Dosage and Administration Information

How to Use Demeprazol — Administration Guidelines

Demeprazol (active ingredient omeprazole) is administered via the oral route, utilizing specialized delayed-release formulations to ensure the substance reaches the small intestine for correct absorption. The medicine must be taken before eating (pre-prandial) and is typically scheduled for once-daily administration.

The specific dose is conditional on the intended use, with standard doses ranging from 20 mg to 40 mg once daily for conditions like erosive esophagitis and gastric ulcers. For certain pathological hypersecretory conditions requiring doses above 80 mg, the total daily quantity is administered in divided doses.

Administration Protocol and Constraints

Instruction Type Detail
Dosing Frequency Typically once daily. High doses are administered in divided doses.
Timing in relation to meals Must be taken before eating a meal.
Preparation / Handling Delayed-release capsules must be swallowed whole; they must not be crushed or chewed to preserve the coating. Oral suspension powder must be mixed only with the specified amount of water.
Course Duration Use may be a short-term course (e.g., 4 to 8 weeks) or long-term maintenance (up to 12 months) as required by the specific indication.
Special Populations A dose reduction to 10 mg once daily is defined for patients with hepatic impairment. No adjustment is required for renal impairment or older adults.

If a dose is missed, the protocol is to take it as soon as possible, but to skip the dose if it is almost time for the next scheduled dose; the dose should never be doubled.

Recent Clinical Evidence

Demeprazol (Omeprazole) was studied for use in a range of conditions related to stomach acid activity. The overall research landscape includes numerous Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies were generally conducted during periods of increased symptom activity and monitored patient-reported outcomes over defined time intervals.


Evidence for Gastric Acid-Related Diseases (GERD and Ulcers)

This section summarizes the structure of the evidence used to assess the medicine in Gastroesophageal Reflux Disease (GERD) and Duodenal and Gastric Ulcers. The research foundation is based on trials that explored outcomes related to physical discomfort and systemic imbalance associated with acid activity. For GERD, RCTs examined endpoints like Esophageal tissue healing rates and the resolution of symptoms (e.g., heartburn). Trials reported measurements of tissue healing within short-term periods (four to eight weeks). Other studies explored how to investigate the maintenance of the tissue state observed during the acute phase, often extending to 12 months. For ulcers, studies primarily monitored ulcer healing rates and examined the frequency of recurrence over time.


Evidence for Pathological Hypersecretion and H. pylori Support

For Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome), the evidence relies on Observational Studies and Long-term case series due to the rarity of these conditions. These studies examine outcomes related to Sustained control of gastric acid secretion, using physiological markers to determine if the desired elevation of intragastric pH was observed. For the management of H. pylori eradication, Demeprazol was studied as part of combination drug regimens. Systematic reviews describe consistent findings related to the overall rate of bacterial eradication and follow-up monitoring to examine the frequency of ulcer recurrence.


Long-Term Research, Specific Populations, and Limitations

Research has explored both acute symptom changes and the management of chronic conditions. Trials related to initial healing typically have follow-up durations that were limited to four to twelve weeks. Longer-term studies were conducted to investigate patterns of sustained response and the frequency of relapse over six to twelve months. Evidence related to long-term effects are not fully established beyond one year.

Most major studies were conducted on the general adult population. Research has explored the use of the medicine in Adolescents and Children, but data for other groups, such as those with certain complex comorbidities, is limited in the published literature. Finally, comparative evidence is lacking for certain endpoints, and for rare conditions, reliance on non-randomized study designs means that certainty remains low compared to large, randomized trials.

Frequently Asked Questions (FAQ)

Common questions about Demeprazol (FAQ)


Q: How long does it typically take to notice the therapeutic effects of Demeprazol?

A: According to official product labeling, the full therapeutic effects of Demeprazol may take 1 to 4 days to be fully achieved after starting the treatment course. This timeframe indicates when the medicine's full acid-reducing effect is typically reached.


Q: How long are the common side effects of Demeprazol expected to last?

A: Official patient information describes common, mild side effects, such as headache or digestive issues. Official guidance suggests that these effects may resolve within a few days or a couple of weeks after treatment begins.


Q: Does the official product information warn about interactions with herbal supplements?

A: Yes, official drug information explicitly warns about potential interactions with certain herbal products. Specifically, St. John’s Wort and Ginkgo biloba are noted as substances that may affect how the medicine works or is handled by the body.


Q: What is the interaction profile of Demeprazol with caffeine-containing products?

A: Studies referenced in official data indicate that Demeprazol does not appear to affect the metabolism of caffeine in the body. However, patient information often notes that limiting caffeine may be beneficial, as it is a substance known to aggravate the symptoms of acid-related conditions.


Q: Are there specific symptoms that warrant contacting a healthcare provider, according to safety information?

A: The regulatory label specifies symptoms that require prompt medical evaluation. These include signs of severe allergic reactions (such as blistering skin), unexplained weight loss, trouble swallowing, or persistent diarrhea. This information is provided to guide patients on when a medical evaluation for serious safety concerns may be needed.


Q: Does Demeprazol interact with alcohol?

A: Drug interaction databases report that no direct drug-drug interaction is found between Demeprazol and alcohol. Regulatory information often describes alcohol as a substance that can aggravate the symptoms of the underlying condition being treated, suggesting caution.


Q: What is the difference between brand-name Demeprazol and its generic version?

A: Generic and brand-name versions contain the same active ingredient (Omeprazole). Regulatory bodies require generics to demonstrate bioequivalence, ensuring similar absorption and availability in the body as the original brand product.


Q: Are there any differences in efficacy or safety between the generic and brand versions?

A: Regulatory oversight ensures generics meet the necessary quality and safety standards. However, some research has indicated that minor variations in acid-suppressive effect or greater variability among different people may occur compared to the original brand formulation.


Q: Why do some tablets of Demeprazol look different from others (e.g., color or shape)?

A: Differences in color, size, and shape are a result of variations in inactive ingredients and the specific manufacturing process used by different companies. This is particularly true for delayed-release forms that require special protective coatings, which can vary in appearance.


Q: What is the expected timeline for Demeprazol's effects to become fully established?

A: The full therapeutic effect is consistently observed within 1 to 4 days of initiating treatment, according to the official product labeling. This timeframe is consistent with when the medicine’s full action on reducing acid secretion is generally reached.


Q: Does the onset of action differ between different types of patients?

A: Official labeling for the active ingredient notes that the medicine’s systemic availability can vary based on an individual’s metabolism status (how their body breaks down the drug). This variance in metabolism may influence the time it takes for the action of the medicine to become noticeable.


Q: Is feeling tired or drowsy a known side effect of Demeprazol?

A: Tiredness is listed as a common side effect in patient information. Drowsiness or feeling sleepy is also mentioned, often in the context of severe reactions or if the medicine is taken in excess.


Q: What are the potential effects of Demeprazol on sleep patterns?

A: Insomnia (difficulty falling or staying asleep) is listed as an uncommon adverse reaction in the safety profile. Clinical research has also studied the medicine’s use in managing sleep disturbances associated with the underlying acid condition.


Q: What specific vitamins or minerals are known to interact with Demeprazol?

A: Official reports indicate that long-term use of Demeprazol may be associated with reduced absorption of Vitamin B12 and minerals such as iron and zinc. This is a factor considered for patients on extended treatment courses.


Q: Are there any foods that affect the way Demeprazol works?

A: The timing of administration relates to meals, but there are no direct drug-food interactions described. Patient guidelines often describe specific foods like fatty, acidic, or spicy items as those that may aggravate the underlying condition, suggesting caution.


Q: What are the most cited research themes related to Demeprazol?

A: The core research base for Demeprazol focuses on key themes, including its acid suppression effectiveness, the healing rates for ulcers and esophageal tissue, its long-term safety profile (e.g., bone fracture risk), and its use as part of combination drug regimens.


Q: Where can I find published research or evidence summaries about Demeprazol?

A: Official patient information, such as the Patient Information Leaflet (PIL) and FDA labeling, is publicly available on regulatory websites. You can often find these summaries through government resources like DailyMed or the NIH’s MedlinePlus.


How should Demeprazol be stored and disposed of?

How to Store and Dispose of Demeprazol (Omeprazole)

Official regulatory documents define specific storage and disposal requirements for Omeprazole delayed-release products.

Storage Conditions

Delayed-release capsules must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The medication must be protected from light and moisture, requiring the container to be kept tightly closed or stored in the original package.

Specific liquid forms, such as the reconstituted oral suspension, have different rules, requiring refrigeration (2 C to 8 C) and must be discarded after 30 days.

It is mandatory that the product be kept out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired product must be carried out in accordance with local requirements. The product is generally not recommended for disposal via wastewater, as per non-flushing drug guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Demeprazol found in:

A-Z Index: